KBC Group NV Purchases 23,174 Shares of Eli Lilly and Company (NYSE:LLY)

KBC Group NV raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 589,009 shares of the company's stock after purchasing an additional 23,174 shares during the quarter. Eli Lilly and Company accounts for about 1.3% of KBC Group NV's investment portfolio, making the stock its 11th biggest position. KBC Group NV owned about 0.06% of Eli Lilly and Company worth $454,715,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in LLY. Algert Global LLC lifted its holdings in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company's stock worth $456,000 after acquiring an additional 110 shares during the period. Pathway Financial Advisers LLC raised its position in Eli Lilly and Company by 4.2% in the second quarter. Pathway Financial Advisers LLC now owns 1,101 shares of the company's stock worth $982,000 after purchasing an additional 44 shares in the last quarter. Advisory Alpha LLC lifted its stake in Eli Lilly and Company by 6.5% during the second quarter. Advisory Alpha LLC now owns 3,208 shares of the company's stock worth $2,905,000 after purchasing an additional 195 shares during the period. Ted Buchan & Co acquired a new stake in Eli Lilly and Company during the second quarter valued at approximately $1,780,000. Finally, Granite Bay Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $323,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.2 %

Shares of LLY traded down $1.98 on Wednesday, reaching $803.01. 1,826,269 shares of the company's stock were exchanged, compared to its average volume of 3,993,929. The business has a 50 day moving average price of $779.81 and a two-hundred day moving average price of $846.28. Eli Lilly and Company has a 12 month low of $637.00 and a 12 month high of $972.53. The stock has a market capitalization of $762.31 billion, a P/E ratio of 86.81, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The business's revenue was up 20.4% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio is currently 56.22%.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.

Analyst Ratings Changes

Several analysts recently commented on the company. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research note on Thursday, October 31st. Bank of America restated a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research report on Thursday, October 10th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company reduced their target price on Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating on the stock in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $997.22.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.